51 – 60 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Coping and Prognostic Awareness in Patients With Advanced Cancer
(2017) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(22). p.2551-2557
- Contribution to journal › Article
- 2016
-
Mark
Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer : A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup consortium
- Contribution to journal › Scientific review
-
Mark
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
- Contribution to journal › Article
-
Mark
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
- Contribution to journal › Article
-
Mark
Gain of 1q as a prognostic biomarker in Wilms Tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial : A SIOP renal tumours biology consortium study
- Contribution to journal › Article
- 2015
-
Mark
Evolution of Treatments for Peritoneal Metastases From Colorectal Cancer
(2015) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33(18). p.2122-2123
- Contribution to journal › Debate/Note/Editorial
-
Mark
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
(2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(15 Suppl). p.5044-5044
- Contribution to journal › Published meeting abstract
-
Mark
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
(2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(7 Suppl). p.288-288
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Development of novel metastatic prostate cancer cell lines by “organoid” in vitro culture technology.
- Contribution to journal › Article
